Barclays PLC Buys 17,604 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Barclays PLC raised its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 123,071 shares of the company's stock after acquiring an additional 17,604 shares during the quarter. Barclays PLC owned approximately 0.24% of Spyre Therapeutics worth $2,866,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SYRE. F M Investments LLC bought a new stake in Spyre Therapeutics in the 4th quarter valued at about $1,136,000. Legal & General Group Plc raised its position in shares of Spyre Therapeutics by 14.8% in the fourth quarter. Legal & General Group Plc now owns 37,490 shares of the company's stock valued at $873,000 after purchasing an additional 4,824 shares during the period. FMR LLC lifted its stake in shares of Spyre Therapeutics by 15.4% during the 4th quarter. FMR LLC now owns 8,801,266 shares of the company's stock valued at $204,893,000 after buying an additional 1,177,385 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Spyre Therapeutics by 38.8% in the 4th quarter. Wells Fargo & Company MN now owns 24,718 shares of the company's stock worth $575,000 after buying an additional 6,908 shares during the period. Finally, ExodusPoint Capital Management LP grew its stake in Spyre Therapeutics by 71.5% in the 4th quarter. ExodusPoint Capital Management LP now owns 16,691 shares of the company's stock valued at $389,000 after buying an additional 6,958 shares in the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SYRE has been the subject of a number of analyst reports. Leerink Partnrs raised Spyre Therapeutics to a "strong-buy" rating in a report on Tuesday, April 8th. Wedbush reiterated an "outperform" rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, January 13th. Wolfe Research started coverage on shares of Spyre Therapeutics in a report on Tuesday, March 18th. They issued an "outperform" rating and a $27.00 price target on the stock. Leerink Partners assumed coverage on shares of Spyre Therapeutics in a research note on Tuesday, April 8th. They issued an "outperform" rating and a $45.00 target price on the stock. Finally, The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $49.57.

Spyre Therapeutics Stock Performance

SYRE traded down $0.86 during trading on Monday, reaching $14.25. The stock had a trading volume of 53,937 shares, compared to its average volume of 598,900. The business has a 50-day moving average of $15.91 and a 200-day moving average of $22.67. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $40.49. The stock has a market cap of $858.93 million, a PE ratio of -1.91 and a beta of 2.78.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.08. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).